Abstract: The present invention provides a process for catalytically hydrogenating unsaturated phytosterol compounds. The catalyst used for such hydrogenation is an alumina-supported transition metal selected from the group consisting of nickel, palladium, platinum, ruthenium, rhodium and mixtures thereof. The process involves the following steps.

Abstract: A method is described for the preparation of water-soluble derivatives of probucol compounds having the following formula where R1 and R2 are the same or different and are alkyl, alkenyl or aryl having from 1 to 8 carbon atoms, R3, R4, R5 and R6 are the same or different and are alkyl having from 1 to 4 carbon atoms and X and Y are the same or different and are hydrogen or the groups saturated acyl or unsaturated acyl having from 1 to 8 carbon atoms said saturated or unsaturated acyl groups containing a polar or charged functionality.

Abstract: A process is disclosed for the preparation of a piperazine-substituted aliphatic carboxylate having the formula where m and n are individually an integer of from 1 to 6, R and R′ are the same or different and are hydrogen, C1 to C6 alkyl or aryl or heteroaryl that is unsubstituted or is substituted with at least one substituent that is halo, C1 to C6 alkyl or C1 to C6 alkoxy and R″ is C3 to C12 branched alkyl or an organic or inorganic cation. The process comprises treating a solution comprising a compound of the formula wherein m, R and R′ are as defined above and an aliphatic ester of the formula X—(CH2)nCO(O)R″ where X is a leaving group and n and R″ are as defined above, with a base in the presence of an effective amount of a phase transfer catalyst, for a time and at a temperature sufficient to form a piperazine-substituted aliphatic carboxylate.

Abstract: A process is disclosed for the preparation of a piperazine-substituted aliphatic carboxylate having the formula where m and n are individually an integer of from 1 to 6, R and R′ are the same or different and are hydrogen, C1 to C6 alkyl or aryl or heteroaryl that is unsubstituted or is substituted with at least one substituent that is halo, C1 to C6 alkyl or C1 to C6 alkoxy and R″ is C3 to C12 branched alkyl or an organic or inorganic cation. The process comprises treating a solution comprising a compound of the formula wherein m, R and R′ are as defined above and an aliphatic ester of the formula X—(CH2)n—O—CH2—CO(O)R″ where X is a leaving group and n and R″ are as defined above, with an effective amount of a base for a time and at a temperature sufficient to form a piperazine-substituted aliphatic carboxylate.

Abstract: A process is disclosed for the preparation of an imidazolone and the pharmaceutically acceptable salts thereof having the formula ##STR1## wherein R1 and R2 are the same or different and are C1 to C6 alkyl, C2 to C6 alkenyl, C1 to C6 cycloalkyl, aryl either unsubstituted or substituted with at least one substituent selected from the group consisting of C1 to C6 alkyl, C1 to C6 alkoxy and halo or heteroaryl either unsubstituted or substituted with C1 to C6 alkyl or halo;or R1 and R2 taken together with the carbon atom in the imidazolone ring form a carbocyclic or heterocyclic ring having from three to seven members and is saturated or is at least mono unsaturated;R3 is C1 to C6 alkyl, C2 to C6 alkenyl, C3 to C6 cycloalkyl, aryl either unsubstituted or substituted with at least one substituent selected from the group consisting of C1 to C6 alkyl, C1 to C6 alkoxy and halo or heteroaryl either unsubstituted or substituted with C1 to C6 alkyl or halo; and A- is an anion of an organic or inorganic acid.